These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Recommended testing algorithms for NTRK gene fusions in pediatric and selected adult cancers: Consensus of a Singapore Task Force. Lim KHT; Kong HL; Chang KTE; Tan DSW; Tan IBH; Mohamad F; Soh SY; Pang BN; Soo RA; Choo SP; Hsieh WS; Aung L Asia Pac J Clin Oncol; 2022 Aug; 18(4):394-403. PubMed ID: 34806337 [TBL] [Abstract][Full Text] [Related]
27. TRK Inhibition: A New Tumor-Agnostic Treatment Strategy. Kummar S; Lassen UN Target Oncol; 2018 Oct; 13(5):545-556. PubMed ID: 30276762 [TBL] [Abstract][Full Text] [Related]
28. Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients. Perreault S; Chami R; Deyell RJ; El Demellawy D; Ellezam B; Jabado N; Morgenstern DA; Narendran A; Sorensen PHB; Wasserman JD; Yip S Curr Oncol; 2021 Jan; 28(1):346-366. PubMed ID: 33435412 [TBL] [Abstract][Full Text] [Related]
29. Nefarious NTRK oncogenic fusions in pediatric sarcomas: Too many to Trk. Aepala MR; Peiris MN; Jiang Z; Yang W; Meyer AN; Donoghue DJ Cytokine Growth Factor Rev; 2022 Dec; 68():93-106. PubMed ID: 36153202 [TBL] [Abstract][Full Text] [Related]
31. NTRK Fusion-positive Non-small-cell Lung Cancer: The Diagnosis and Targeted Therapy. Haratake N; Seto T Clin Lung Cancer; 2021 Jan; 22(1):1-5. PubMed ID: 33272813 [TBL] [Abstract][Full Text] [Related]
32. Testing algorithm for identification of patients with TRK fusion cancer. Penault-Llorca F; Rudzinski ER; Sepulveda AR J Clin Pathol; 2019 Jul; 72(7):460-467. PubMed ID: 31072837 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Waguespack SG; Drilon A; Lin JJ; Brose MS; McDermott R; Almubarak M; Bauman J; Casanova M; Krishnamurthy A; Kummar S; Leyvraz S; Oh DY; Park K; Sohal D; Sherman E; Norenberg R; Silvertown JD; Brega N; Hong DS; Cabanillas ME Eur J Endocrinol; 2022 Apr; 186(6):631-643. PubMed ID: 35333737 [TBL] [Abstract][Full Text] [Related]
34. Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults. Bebb DG; Banerji S; Blais N; Desmeules P; Gill S; Grin A; Feilotter H; Hansen AR; Hyrcza M; Krzyzanowska M; Melosky B; Noujaim J; Purgina B; Ruether D; Simmons CE; Soulieres D; Torlakovic EE; Tsao MS Curr Oncol; 2021 Jan; 28(1):523-548. PubMed ID: 33467570 [TBL] [Abstract][Full Text] [Related]
35. Targeting TRK: A fast-tracked application of precision oncology and future directions. Kojadinovic A; Laderian B; Mundi PS Crit Rev Oncol Hematol; 2021 Sep; 165():103451. PubMed ID: 34389458 [TBL] [Abstract][Full Text] [Related]
36. Practical instructions for testing and targeted therapy in adult patients with solid tumours with NTRK gene fusion in common clinical practice. Büchler T; Dundr P; Fínek J; Kiss I; Matěj R; Melichar B; Michal M; Petruželka L Klin Onkol; 2020; 33(6):414-419. PubMed ID: 33685189 [TBL] [Abstract][Full Text] [Related]
37. Type I inhibitors of tropomyosin receptor kinase (Trk): a 2020-2022 patent update. Jaworski C; Iliev P; Wängler C; Wängler B; Page B; Schirrmacher R; Bailey JJ Expert Opin Ther Pat; 2023; 33(7-8):503-521. PubMed ID: 37735897 [TBL] [Abstract][Full Text] [Related]
38. NTRK fusions in colorectal cancer: clinical meaning and future perspective. Ratti M; Grizzi G; Passalacqua R; Lampis A; Cereatti F; Grassia R; Hahne JC Expert Opin Ther Targets; 2021 Aug; 25(8):677-683. PubMed ID: 34488530 [TBL] [Abstract][Full Text] [Related]
39. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. Hong DS; Bauer TM; Lee JJ; Dowlati A; Brose MS; Farago AF; Taylor M; Shaw AT; Montez S; Meric-Bernstam F; Smith S; Tuch BB; Ebata K; Cruickshank S; Cox MC; Burris HA; Doebele RC Ann Oncol; 2019 Feb; 30(2):325-331. PubMed ID: 30624546 [TBL] [Abstract][Full Text] [Related]